Thank you for attending THSNA 2026. The virtual meeting is now closed.
| Anticoagulation in patients with inherited bleeding disorders Kimberly Youkhana. |
Abstract
Anticoagulation in Patients with Inherited Bleeding Disorders: Between a Clot and a Hard Place.
Background: As survival in inherited bleeding disorders (IBDs) approaches that of the general population, more adults with hemophilia, von Willebrand disease, factor XI deficiency, and inherited platelet function disorders present with atrial fibrillation (AF), acute coronary syndromes (ACS), and venous thromboembolism (VTE). Bleeding phenotype and factor deficiency do not reliably protect against arterial or venous thrombosis, yet conventional anticoagulation substantially increases bleeding risk. Evidence is limited to guidelines, registries, and small case series, leaving clinicians uncertain how to balance thrombotic and hemorrhagic risks in this high‑risk population.
Objectives: To (1) outline a practical framework for thrombotic and bleeding risk assessment in adults with IBDs who require anticoagulation; (2) summarize disorder‑specific considerations across major IBD subtypes; (3) review real‑world management strategies for AF, ACS, and VTE; and (4) illustrate decision‑making using a detailed AF case in a person with hemophilia A.
Methods: This presentation synthesizes contemporary clinical practice guidance, observational data, and published case series on antithrombotic therapy in IBDs, with a focus on 2020–2025 literature. A conceptual framework integrates standard thrombosis scores (CHA₂DS₂‑VASc, Wells) with bleeding assessment that incorporates factor level, inhibitor status, and lifetime bleeding phenotype rather than severity alone. A representative case of a man with hemophilia A and AF is expanded to include detailed bleeding history, factor prophylaxis, comorbidities, and patient preferences, allowing live application of risk tools and shared decision‑making.
Results: The framework confirms that standard thrombotic risk scores remain applicable in IBDs, whereas bleeding risk is best captured by clinical phenotype and current factor trough levels. For hemophilia and von Willebrand disease, long‑term oral anticoagulation is generally feasible when factor VIII, IX, or VWF activity can be maintained at troughs of at least 20–30% with prophylaxis. In severe hemophilia with inhibitors, the risk of uncontrollable bleeding often precludes full‑dose anticoagulation, although emicizumab may create new options in select patients. In factor XI deficiency, natural thrombotic protection and emerging FXI inhibitors highlight a distinct risk‑benefit profile. Platelet function disorders require highly individualized approaches, often using reduced‑dose direct oral anticoagulants (DOACs) or low‑molecular‑weight heparin with careful monitoring.
For AF, three main strategies emerge: (1) no long‑term anticoagulation with aggressive risk‑factor control in carefully selected patients; (2) DOAC‑based anticoagulation combined with intensified factor prophylaxis to maintain safe trough levels; and (3) left atrial appendage–based interventions, with or without catheter ablation, using short‑term peri‑procedural anticoagulation and modified antiplatelet regimens. ACS management emphasizes high peri‑procedural factor targets, preference for short‑acting parenteral anticoagulants, and abbreviated dual antiplatelet therapy. VTE can often be treated with standard 3–6‑month courses of anticoagulation under factor coverage, with extended therapy reserved for selected high‑risk patients.
Conclusions: Anticoagulation in patients with inherited bleeding disorders is complex but feasible when guided by a structured assessment of thrombotic risk, bleeding phenotype, and achievable factor levels. Bleeding disorders do not obviate the need for stroke and VTE prevention, particularly in older patients with multiple cardiovascular comorbidities. DOACs, combined with tailored factor prophylaxis targeting trough levels ≥20–30%, represent a preferred strategy for many patients, while catheter‑based AF interventions and left atrial appendage occlusion offer alternatives for those with prohibitive long‑term bleeding risk. Individualized, multidisciplinary decision‑making that incorporates patient values is essential to safely navigate “between a clot and a hard place.”
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.